Serum metabolic signatures for Alzheimer’s Disease reveal alterations in amino acid composition: a validation study
-
Published:2024-01-05
Issue:1
Volume:20
Page:
-
ISSN:1573-3890
-
Container-title:Metabolomics
-
language:en
-
Short-container-title:Metabolomics
Author:
Nielsen Jonas Ellegaard,Andreassen Trygve,Gotfredsen Charlotte Held,Olsen Dorte Aalund,Vestergaard Karsten,Madsen Jonna Skov,Kristensen Søren Risom,Pedersen Shona
Abstract
Abstract
Introduction
Alzheimer’s Disease (AD) is complex and novel approaches are urgently needed to aid in diagnosis. Blood is frequently used as a source for biomarkers; however, its complexity prevents proper detection. The analytical power of metabolomics, coupled with statistical tools, can assist in reducing this complexity.
Objectives
Thus, we sought to validate a previously proposed panel of metabolic blood-based biomarkers for AD and expand our understanding of the pathological mechanisms involved in AD that are reflected in the blood.
Methods
In the validation cohort serum and plasma were collected from 25 AD patients and 25 healthy controls. Serum was analysed for metabolites using nuclear magnetic resonance (NMR) spectroscopy, while plasma was tested for markers of neuronal damage and AD hallmark proteins using single molecule array (SIMOA).
Results
The diagnostic performance of the metabolite biomarker panel was confirmed using sparse-partial least squares discriminant analysis (sPLS-DA) with an area under the curve (AUC) of 0.73 (95% confidence interval: 0.59–0.87). Pyruvic acid and valine were consistently reduced in the discovery and validation cohorts. Pathway analysis of significantly altered metabolites in the validation set revealed that they are involved in branched-chain amino acids (BCAAs) and energy metabolism (glycolysis and gluconeogenesis). Additionally, strong positive correlations were observed for valine and isoleucine between cerebrospinal fluid p-tau and t-tau.
Conclusions
Our proposed panel of metabolites was successfully validated using a combined approach of NMR and sPLS-DA. It was discovered that cognitive-impairment-related metabolites belong to BCAAs and are involved in energy metabolism.
Funder
Qatar National Library
Publisher
Springer Science and Business Media LLC
Subject
Clinical Biochemistry,Biochemistry,Endocrinology, Diabetes and Metabolism
Reference38 articles.
1. Ahmed, S. S., Santosh, W., Kumar, S., & Christlet, H. T. T. (2009). Metabolic profiling of Parkinson’s disease: Evidence of biomarker from gene expression analysis and rapid neural network detection. Journal of Biomedical Science,16(1), 63. https://doi.org/10.1186/1423-0127-16-63 2. Baird, A. L., Westwood, S., & Lovestone, S. (2015). Blood-based proteomic biomarkers of Alzheimer’s disease pathology. Frontiers in Neurology. https://doi.org/10.3389/fneur.2015.00236 3. Bak, L. K., Schousboe, A., & Waagepetersen, H. S. (2006). The glutamate/GABA-glutamine cycle: Aspects of transport, neurotransmitter homeostasis and ammonia transfer. Journal of Neurochemistry,98(3), 641–653. https://doi.org/10.1111/j.1471-4159.2006.03913.x 4. Burnham, S. C., Faux, N. G., Wilson, W., Laws, S. M., Ames, D., Bedo, J., et al. (2014). A blood-based predictor for neocortical Aβ burden in Alzheimer’s disease: results from the AIBL study. Molecular Psychiatry,19(4), 519–526. https://doi.org/10.1038/mp.2013.40 5. Cai, Q., Takemura, G., & Ashraf, M. (1995). Antioxidative properties of histidine and its effect on myocardial injury during ischemia/reperfusion in isolated rat heart. Journal of Cardiovascular Pharmacology,25(1), 147–155. https://doi.org/10.1097/00005344-199501000-00023
|
|